Cargando…
Intensity-modulated Radiotherapy for Rectal Cancer in the UK in 2020
AIMS: Preoperative (chemo)radiotherapy followed by total mesorectal excision is the current standard of care for patients with locally advanced rectal cancer. The use of intensity-modulated radiotherapy (IMRT) for rectal cancer is increasing in the UK. However, the extent of IMRT implementation and...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
W.B. Saunders
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985673/ https://www.ncbi.nlm.nih.gov/pubmed/33423883 http://dx.doi.org/10.1016/j.clon.2020.12.011 |
_version_ | 1783668296355151872 |
---|---|
author | Hanna, C.R. Slevin, F. Appelt, A. Beavon, M. Adams, R. Arthur, C. Beasley, M. Duffton, A. Gilbert, A. Gollins, S. Harrison, M. Hawkins, M.A. Laws, K. O'Cathail, S. Porcu, P. Robinson, M. Sebag-Montefiore, D. Teo, M. Teoh, S. Muirhead, R. |
author_facet | Hanna, C.R. Slevin, F. Appelt, A. Beavon, M. Adams, R. Arthur, C. Beasley, M. Duffton, A. Gilbert, A. Gollins, S. Harrison, M. Hawkins, M.A. Laws, K. O'Cathail, S. Porcu, P. Robinson, M. Sebag-Montefiore, D. Teo, M. Teoh, S. Muirhead, R. |
author_sort | Hanna, C.R. |
collection | PubMed |
description | AIMS: Preoperative (chemo)radiotherapy followed by total mesorectal excision is the current standard of care for patients with locally advanced rectal cancer. The use of intensity-modulated radiotherapy (IMRT) for rectal cancer is increasing in the UK. However, the extent of IMRT implementation and current practice was not previously known. A national survey was commissioned to investigate the landscape of IMRT use for rectal cancer and to inform the development of national rectal cancer IMRT guidance. MATERIALS AND METHODS: A web-based survey was developed by the National Rectal Cancer IMRT Guidance working group in collaboration with the Royal College of Radiologists and disseminated to all UK radiotherapy centres. The survey enquired about the implementation of IMRT with a focus on the following aspects of the workflow: dose fractionation schedules and use of a boost; pre-treatment preparation and simulation; target volume/organ at risk definition; treatment planning and treatment verification. A descriptive statistical analysis was carried out. RESULTS: In total, 44 of 63 centres (70%) responded to the survey; 30/44 (68%) and 36/44 (82%) centres currently use IMRT to treat all patients and selected patients with rectal cancer, respectively. There was general agreement concerning several aspects of the IMRT workflow, including patient positioning, use of intravenous contrast and bladder protocols. Greater variation in practice was identified regarding rectal protocols; use of a boost to primary/nodal disease; target volume delineation; organ at risk delineation and dose constraints and treatment verification. Delineation of individual small bowel loops and daily volumetric treatment verification were considered potentially feasible by most centres. CONCLUSION: This survey identified that IMRT is already used to treat rectal cancer in many UK radiotherapy centres, but there is heterogeneity between centres in its implementation and practice. These results have been a valuable aid in framing the recommendations within the new National Rectal Cancer IMRT Guidance. |
format | Online Article Text |
id | pubmed-7985673 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | W.B. Saunders |
record_format | MEDLINE/PubMed |
spelling | pubmed-79856732021-04-01 Intensity-modulated Radiotherapy for Rectal Cancer in the UK in 2020 Hanna, C.R. Slevin, F. Appelt, A. Beavon, M. Adams, R. Arthur, C. Beasley, M. Duffton, A. Gilbert, A. Gollins, S. Harrison, M. Hawkins, M.A. Laws, K. O'Cathail, S. Porcu, P. Robinson, M. Sebag-Montefiore, D. Teo, M. Teoh, S. Muirhead, R. Clin Oncol (R Coll Radiol) Original Article AIMS: Preoperative (chemo)radiotherapy followed by total mesorectal excision is the current standard of care for patients with locally advanced rectal cancer. The use of intensity-modulated radiotherapy (IMRT) for rectal cancer is increasing in the UK. However, the extent of IMRT implementation and current practice was not previously known. A national survey was commissioned to investigate the landscape of IMRT use for rectal cancer and to inform the development of national rectal cancer IMRT guidance. MATERIALS AND METHODS: A web-based survey was developed by the National Rectal Cancer IMRT Guidance working group in collaboration with the Royal College of Radiologists and disseminated to all UK radiotherapy centres. The survey enquired about the implementation of IMRT with a focus on the following aspects of the workflow: dose fractionation schedules and use of a boost; pre-treatment preparation and simulation; target volume/organ at risk definition; treatment planning and treatment verification. A descriptive statistical analysis was carried out. RESULTS: In total, 44 of 63 centres (70%) responded to the survey; 30/44 (68%) and 36/44 (82%) centres currently use IMRT to treat all patients and selected patients with rectal cancer, respectively. There was general agreement concerning several aspects of the IMRT workflow, including patient positioning, use of intravenous contrast and bladder protocols. Greater variation in practice was identified regarding rectal protocols; use of a boost to primary/nodal disease; target volume delineation; organ at risk delineation and dose constraints and treatment verification. Delineation of individual small bowel loops and daily volumetric treatment verification were considered potentially feasible by most centres. CONCLUSION: This survey identified that IMRT is already used to treat rectal cancer in many UK radiotherapy centres, but there is heterogeneity between centres in its implementation and practice. These results have been a valuable aid in framing the recommendations within the new National Rectal Cancer IMRT Guidance. W.B. Saunders 2021-04 /pmc/articles/PMC7985673/ /pubmed/33423883 http://dx.doi.org/10.1016/j.clon.2020.12.011 Text en © 2020 The Royal College of Radiologists. Published by Elsevier Ltd. http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Original Article Hanna, C.R. Slevin, F. Appelt, A. Beavon, M. Adams, R. Arthur, C. Beasley, M. Duffton, A. Gilbert, A. Gollins, S. Harrison, M. Hawkins, M.A. Laws, K. O'Cathail, S. Porcu, P. Robinson, M. Sebag-Montefiore, D. Teo, M. Teoh, S. Muirhead, R. Intensity-modulated Radiotherapy for Rectal Cancer in the UK in 2020 |
title | Intensity-modulated Radiotherapy for Rectal Cancer in the UK in 2020 |
title_full | Intensity-modulated Radiotherapy for Rectal Cancer in the UK in 2020 |
title_fullStr | Intensity-modulated Radiotherapy for Rectal Cancer in the UK in 2020 |
title_full_unstemmed | Intensity-modulated Radiotherapy for Rectal Cancer in the UK in 2020 |
title_short | Intensity-modulated Radiotherapy for Rectal Cancer in the UK in 2020 |
title_sort | intensity-modulated radiotherapy for rectal cancer in the uk in 2020 |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985673/ https://www.ncbi.nlm.nih.gov/pubmed/33423883 http://dx.doi.org/10.1016/j.clon.2020.12.011 |
work_keys_str_mv | AT hannacr intensitymodulatedradiotherapyforrectalcancerintheukin2020 AT slevinf intensitymodulatedradiotherapyforrectalcancerintheukin2020 AT appelta intensitymodulatedradiotherapyforrectalcancerintheukin2020 AT beavonm intensitymodulatedradiotherapyforrectalcancerintheukin2020 AT adamsr intensitymodulatedradiotherapyforrectalcancerintheukin2020 AT arthurc intensitymodulatedradiotherapyforrectalcancerintheukin2020 AT beasleym intensitymodulatedradiotherapyforrectalcancerintheukin2020 AT dufftona intensitymodulatedradiotherapyforrectalcancerintheukin2020 AT gilberta intensitymodulatedradiotherapyforrectalcancerintheukin2020 AT gollinss intensitymodulatedradiotherapyforrectalcancerintheukin2020 AT harrisonm intensitymodulatedradiotherapyforrectalcancerintheukin2020 AT hawkinsma intensitymodulatedradiotherapyforrectalcancerintheukin2020 AT lawsk intensitymodulatedradiotherapyforrectalcancerintheukin2020 AT ocathails intensitymodulatedradiotherapyforrectalcancerintheukin2020 AT porcup intensitymodulatedradiotherapyforrectalcancerintheukin2020 AT robinsonm intensitymodulatedradiotherapyforrectalcancerintheukin2020 AT sebagmontefiored intensitymodulatedradiotherapyforrectalcancerintheukin2020 AT teom intensitymodulatedradiotherapyforrectalcancerintheukin2020 AT teohs intensitymodulatedradiotherapyforrectalcancerintheukin2020 AT muirheadr intensitymodulatedradiotherapyforrectalcancerintheukin2020 |